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Abstract
The characterization of circulating endothelial progenitor cells (EPCs) is fundamental to any
study related to angiogenesis. Unfortunately, current literature lacks consistency in the defi-
nition of EPC subsets due to variations in isolation strategies and inconsistencies in the use
of lineage markers. Here we address critical points in the identification of hematopoietic pro-
genitor cells (HPCs), circulating endothelial cells (CECs), and culture-generated outgrowth
endothelial cells (OECs) from blood samples of healthy adults (AB) and umbilical cord
(UCB). Peripheral blood mononuclear cells (PBMCs) were enriched using a Ficoll-based
gradient followed by an optimized staining and gating strategy to enrich for the target cells.
Sorted EPC populations were subjected to RT-PCR for tracing the expression of markers
beyond the limits of cell surface-based immunophenotyping. Using CD34, CD133 and c-kit
staining, combined with FSC and SSC, we succeeded in the accurate and reproducible
identification of four HPC subgroups and found significant differences in the respective pop-
ulations in AB vs. UCB. Co-expression analysis of endothelial markers on HPCs revealed a
complex pattern characterized by various subpopulations. CECs were identified by using
CD34, KDR, CD45, and additional endothelial markers, and were subdivided according to
their apoptotic state and expression of c-kit. Comparison of UCB-CECs vs. AB-CECs
revealed significant differences in CD34 and KDR levels. OECs were grown from PBMC-
fractions We found that viable c-kit+ CECs are a candidate circulating precursor for CECs.
RT-PCR to angiogenic factors and receptors revealed that all EPC subsets expressed
angiogenesis-related molecules. Taken together, the improvements in immunophenotyping
and gating strategies resulted in accurate identification and comparison of better defined
cell populations in a single procedure.
Introduction
Over the last decades circulating EPCs have been extensively studied in the context of both
health and disease. EPCs take part in neovascularization and their levels are used to monitor
the effects of therapy [1–4]. Notably, the term EPC is not only used for cells with genuine
endothelial lineages, but also for other cell types supporting neovascularization, including
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hematopoietic progenitor cells (HPCs) [1, 5–8]. HPCs are bone marrow derived [9] and home
to ischemic or neoplastic tissues that secrete chemo-attractants and, following differentiation,
contribute to angiogenesis by secreting proangiogenic factors [10–12]. Another subset of cir-
culating EPCs is capable of generating in vitro outgrowth endothelial cells (OECs). The in vivo
equivalent of OECs is believed to contribute to vascular regeneration [7, 13–17]. While most
circulating endothelial cells (CECs) are damaged or apoptotic mature endothelial cells with no
progenitor potential [18–21], there may well be a small CEC fraction of viable endothelial pro-
genitors from which OECs can be grown. However, the kinship of CECs and OECS has not
been proven, mainly because authors used unsorted PBMCs or PBMCs enriched for specific
markers using magnetic beads, instead of FACS sorting [1, 7, 20, 22–26]. The accurate identifi-
cation of EPC subsets, and their subdivision, is challenged by the low frequencies of these cells
in the bloodstream, the different ways of their isolation, and the discrepant immuno-pheno-
typical definitions used [1, 5, 8, 23, 24, 27–31]. The introduction of validated procedures of iso-
lation and work-up would greatly improve accurate comparisons of the various populations
and literature data on the EPC subsets, and shed more light on the genuine source of OECs
[7, 32].
Here we present a protocol for the accurate identification, characterization, and subdivision
of HPCs, CECs and culture-derived OECs from peripheral blood samples of healthy adults
(AB) and umbilical cord blood (UCB). The procedure includes the analysis of stem cell mark-
ers [32] and RT-PCR on sorted cells allows for the detection of markers beyond cell-surface
expression. By following the procedures described we succeeded in demonstrating the similari-
ties between OECs and CECs, suggestive of kinship between these populations. PCR analysis
to the distinct EPC subsets and HUVECs for the detection of angiogenic factors and receptors
revealed angiogenic capacities of all subsets.
Material & methods
Medical-ethical considerations
This study was approved by the Medical Ethics Committee of the Erasmus Medical Center,
Rotterdam, The Netherlands (MEC-2011-313) and carried out in adherence to the Code of
Conduct of the Federation of Medical Scientific Societies in the Netherlands (http://www.
federa.org/codes-conduct).
Blood samples and preparation
Eighteen samples of adult peripheral blood (24–40 ml) and 15 samples of umbilical cord blood
(12 ml) were used for this study. The samples were collected in BD vacutainer EDTA tubes
and stored at room temperature in the dark for18 hours. Blood was then diluted 1:1 with
PBS-0,5 mM EGTA, and PBMCs were isolated using Ficoll Paque plus (GE Healthcare).
FACS analysis and sorting
PBMCs were incubated with 10% mouse serum to block unspecific antibody binding and
stained 20’ with specific antibodies (S1 Table). To get saturation, OECs/HUVECs were stained
with 1 μg Ab/106 cells/200 μl, and PBMCs with 1.5 μg Ab/107 cells/200 μl. KDR staining was
amplified using a 3-step protocol: 1) anti-KDR-APC; 2) anti-APC-biotin; 3) streptavidin-APC.
After staining the cells were washed twice and re-suspended in PBS, 10% BSA, 0,1μg/ml
Hoechst 3h3258 to mark dead cells. All steps were performed on ice. Live nuclear staining was
performed with the cell permeant Hoechst33342 (Sigma-Aldrich), 10μM for 30’ at RT. FACS
analysis/sorting was performed with a BD FACS Aria III (BD Biosciences, New Jersey, US)
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using the parameters listed in (S1 Table). In the FSC/SSC plot, mononuclear cells were selected
using a gate for high FSC cells excluding residual granulocytes, cellular debris and small parti-
cles (Fig 1 and S1 Fig). In the SSC-H/SSC-W and FSC-H/FSC-W plots single cells were
selected and doublets excluded. Avital cells were gated out in a Hoechst-A/FSC-A plot. For the
initial setup, fluorescence minus one (FMO) and isotype controls were used for each antibody
(S2 Fig).
Fig 1. Basic strategies of sample preparation and FACS analysis. A. FACS plots of Ficoll-enriched PBMCs vs. RBC lysis-based
preparations. To prevent exclusion of large cells, a large mononuclear-cell gate was applied. B. Ratios of enrichment of total live
PBMCs, lymphocytes, monocytes, HPCs (as defined in Fig 2) and CECs (as defined in Fig 3) by Ficoll vs. RBC lysis. C-D. Examples of
reduction of background (auto-fluorescence) by stringent exclusion of dead cells using Hoechst 33258 (C) and (residual) granulocytes
(D). E. Basic procedure used, in addition to standard acquisition (1x106 total events), to enrich for target cells by discarding triple CD34/
CD133/KDR negative events. Upper left plot: selection of CD34+ and KDR+ cells; lower left plot: selection of CD34+ and CD133+ cells.
Right panels: result of a “Join (Or) gate” in FACS DIVA. KDR+ CD34+ (upper plot) and CD133+ CD34+ (lower plot) populations are
better visualized. F. Delineation of a scale of FACS-based fluorescence levels. Negative peak = unstained or isotype control; low
(dim) = within 1 log from negative; high (bright) = more than 1 log from negative and ranging from moderately high (1st to 2nd log above
negative) to very high (3rd log or higher). “Medium” is sometimes used to define populations in between low and high.
https://doi.org/10.1371/journal.pone.0184895.g001
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Annexin V staining
Following immunostaining, 5μl of Annexin-V-FITC (BD) or Annexin-V-biotin (BD), were
added to 500,000 PBMCs in Annexin Buffer and left 20’ on ice, followed by one washing step.
Incubation with Annexin V-biotin was followed by streptavidin-APC staining. The FACS
analysis was carried out in Annexin V buffer, 0,1μg/ml Hoechst 33258.
Generation of outgrowth endothelial cells
PBMCs were re-suspended in endothelial cell medium (EGM-2 + BulletKit; Lonza), seeded in
culture flasks (Corning, polystyrene) at 2.5x106 cells/cm2, and incubated at 37˚C, 5% CO2.
Medium was changed daily. When OECs reached 80% confluence, cells were passaged using
Accutase (Sigma-Aldrich). Gelatin, collagen-I, and fibronectin coating were tested and com-
pared to non-coated plates. Because coating did not significantly affect the generation of OECs
we used uncoated plates.
RNA Isolation and RT-PCR
Gene expression was analyzed in HPCs (12 UCB and 10 AB; 2,000–70,000 cells), CECs (2 UCB
and 1 AB; 600–2,000 cells), control leukocytes (3 UCB and 6 AB, CD34-CD133-KDR-CD45+),
OECs (3 UCB and 1 AB; 500,000 cells), and HUVECs (2 separate cell lines, 500,000 cells). Cells
were lysed in RLT buffer (Qiagen RNeasy micro kit) containing 1% β-mercaptoethanol, vor-
texed for 1’ and stored at -80˚C. RNA was isolated using the RNeasy micro kit (Qiagen).
cDNA was synthesized using the qScript cDNA SuperMix kit from Quanta. Due to low num-
bers of sorted HPCs and CECs, the PreAmp cDNA amplification kit (Quanta) was used (up to
100 genes). Amplified cDNA was diluted 20-fold. RT-PCR was performed following manufac-
turer instructions (Quanta) and 200nM primers. Pre-amplification was extensively validated
to determine whether the correct proportion of transcripts was retained. PCR primers are
listed in (S1 Table). In order to analyze the cells at functional level, RT-PCR to 10 angiogenic
factors and receptors (apelin, PDFDβ, PDGFR, SCF, FGF, EGF, EGFR, VEGFA, Tie-1 and
Tie-2) was carried out for all EPC subsets.
Statistical analysis
The non-parametric Mann-Whitney U test in SPSS (version 21.0.0.1) was used to determine
differences in HPC and CEC frequencies and in gene expression.
Results
Sample preparation and FACS analysis
The mononuclear cell fraction containing the EPC subsets was on average six times enriched
by using Ficoll as compared to standard RBC lysis buffer, thereby leaving the ratios between
the PBMCs and EPC subsets unaltered (Panels A and B in Fig 1 and Panel A and B in S1 Fig).
The background caused by autofluorescence and unspecific antibody binding was reduced by
excluding dead cells by Hoechst 33258 staining (Panel C in Fig 1) and residual non-mononu-
clear cells (Panel D in Fig 1) by gating them out in a FSC/SSC plot. The mononuclear gate
applied was large enough to include CECs eventually present in the high FSC region (Panel A
in Fig 1 and Panel C in S1 Fig). Spillover between fluorochromes was minimized by using one
fluorescent channel per laser, with the exception of the 405 nm laser (S1 Table). Bright anti-
bodies or signal amplification were used to gain sufficient resolution for each marker. The
visualization of rare cells was improved by discarding triple CD34/KDR/CD133 negative
events, thereby reducing data overload and enabling the recording of larger sized samples. By
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setting a threshold around 2% positive events, the target cells were ~ 50 times enriched (Panel
E in Fig 1) and reliable visualization was accomplished for populations with a frequency as low
as CECs in AB (~1/1106 PBMCs)[21]. To enable direct visual comparison of fluorescent levels
between populations and samples, a common scale of fluorescence intensity based on litera-
ture and our own data was applied in all FACS plots (Panel F in Fig 1) [1, 33].
Characterization and quantification of HPCs
Following current definitions [5, 17, 34], HPCs were initially identified as a CD34+/high cluster
and refined by gating CD45low. Based on the expression intensities for CD133, HPCs were
sub-divided in CD133high, CD133low, and CD133neg cells (Panela A and B in Fig 2) [1, 5, 17,
34]. A bright antibody was necessary to properly visualize different CD133 levels (Panel A in
Fig 2). HPCs were located in between lymphocytes and monocytes in the FSC/SSC plot (Panel
C in Fig 2). Gating on FSC/SSC converged with CD45-based gating, and provided further
purification of HPCs, mainly by cleaning the CD133neg subpopulation. By using both CD45
and FSC/SSC, HPC gating was refined over previous protocols. To verify the identity of the
HPCs we tested the expression of CD133 and c-kit by RT-PCR on sorted HPC-fractions. The
expression of CD133 was verified by RT-PCR and was at low levels also found in the CD133neg
subpopulation (Panel E in Fig 2). mRNA expression for c-kit was found in all three subpopula-
tions (Panel E in Fig 2) and appeared to be high and independent of CD133 levels. Overall,
HPCs (calculated as ratio over CD45+ PBMCs) were 5.8 times more frequent in UCB than in
AB (Panel F in Fig 2). The frequencies of the three CD133-based subpopulations differed
between UCB and AB. CD133high HPCs represented 72% of total HPCs in UCB but only 43%
in AB.
Further HPC sub-classification was obtained by simultaneous staining for c-kit and CD133.
Four sub-populations of HPCs were distinguished: CD133negc-kithigh, CD133lowc-kithigh,
CD133highc-kithigh, and CD133highc-kitneg/low (the last only observed in AB samples) (Panels A
and B in Fig 3). In addition, the expression of CD34 and CD45 was found to be positively asso-
ciated with CD133 levels but independent of c-kit levels. CD133neg HPCs have the highest c-
kit levels (Panel A in Fig 3 and Panels A-C in S3 Fig). Expression of the endothelial markers
KDR, CD144, and CD146 was only observed in sporadic HPCs (Panels C-E in Fig 3). CD105
was expressed at very low levels, only partially crossing the negative gate. Preliminary co-
expression analysis revealed that KDR, CD146, CD144, CD105 do not converge to the identifi-
cation of a single population of EPCs [8], but each marker mostly identifies small independent
subpopulations, (Panels D and E in Fig 3 and Panels D-F in S3 Fig).
Characterization and quantification of CECs
CECs were identified as CD34+KDR+ cells (Panel A in Fig 4) that are negative for CD45 (Panel
B in Fig 4). Brightnesss of the staining was essential for proper CEC identification. Visualiza-
tion of KDR required signal amplification (S1 Table) and the staining intensity of CD45 was
crucial for separating CD45neg CECs from sporadic CD45lowKDR+ HPCs across the CD45neg
gate (Panel B in Fig 4). The frequency of CECs was significantly higher in UCB (14/106 CD45+
PBMCs) than in AB (1,9/106 CD45+ PBMCs) (Panels C and D in Fig 4). The CD34 and KDR
levels encountered in UCB-CECs (mainly CD34highKDR+/high) differed from those in
AB-CECs (mainly CD34medKDRlow) (Panel C in Fig 4). The CECs expressed the endothelial
markers CD146, CD144 and CD105 (Panel E in Fig 4 and Panel B in S4 Fig), which largely
overlapped with KDR, confirming the endothelial identity of the selected population. Based on
our data, CD146 and CD144 can be regarded as good substitutes for KDR in CEC identifica-
tion, or as additional markers to refine the population. Immunopositivity for CD105 should be
Characterization of endothelial progenitor cell subsets
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carefully evaluated since CD105-expressing HPCs (Panel C in Fig 3) that pass the CD45 nega-
tive gate may contaminate the CEC population. Notably, KDR yielded the cleanest background
on HPCs followed by CD144, and CD146 (Panel C in Fig 3), and the best match (98% vs. only
90% with CD146 and CD144) in CEC-identification (Panel E in Fig 4 and Panel B in S4 Fig).
Fig 2. Identification and characterization of HPCs. A. Upper panel: HPCs in UCB and AB are initially selected as CD34+/hi cells
and subdivided into CD133hi, CD133low and CD133neg. Lower panel: discrimination between CD133 levels is partially missed using a
less bright antibody. B. HPCs are refined by gating a single peak in the CD45low region. Left plot: CD45 gating on raw HPCs (CD34+/hi
events). Right plot: CD45 gating on CD34+/hi events pre-refined by FSC/SSC. CD45 levels slightly increase with CD133 expression
(see also S3 Fig), still remaining within the “low” gate. The % of match of raw or pre-refined HPCs with the CD45low gate is indicated
in the plots for each population. C. In a FSC/SSC plot, HPCs appear as a tight cluster in between lymphocytes and monocytes. Upper
panel: FSC/SSC gating on raw HPCs (CD34+/hi events). Lower panel: FSC/SSC gating on CD34+/hi events pre-refined by CD45
levels. The % of match of raw or pre-refined HPCs with the FSC/SSC gate is indicated in the plots for each population. Comparison of
B (left vs. right plot) and C (upper vs. lower panel) shows that CD45 and FSC/SSC gating converge to the identification of pure HPCs:
partial overlapping in HPC cleaning indicates that the two approaches identify the same population, however each approach also
provides some independent contribution to HPC purification. The less pure and most affected by cleaning gates appears the
CD133neg fraction. D. FACS plots showing the distribution of pure HPCs (CD34 vs. CD133 plot) in UCB vs. AB. E. CD133 and c-kit
RT-PCR in CD34+CD133+ cells (n = 22); CD34+CD133- cells (n = 17) and CD34-KDR-CD133- PBMCs (n = 8) isolated from UCB.
CD133 mRNA is detected in both CD133+ and CD133- HPCs, although at different levels. c-kit mRNA further confirms the HPC
identity of the CD34+CD133- cells. F. Left panel: median frequency of HPCs in UCB (5,6 in 1*103 CD45+ PBMCs) and AB (0,97 in
1*103 CD45+ PBMCs, significantly lower than in UCB, Z = -4,9; p = 1,00E-06). Middle panel: percentage ± SD of the three
CD133-based HPC subpopulations in UCB vs. AB. Right panel: RT-PCR confirms higher CD133 expression by total UCB-HPCs than
AB-HPCs.
https://doi.org/10.1371/journal.pone.0184895.g002
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RT-PCR confirmed that KDR expression is CEC-specific and absent in HPCs (Panel C in S4
Fig). Because CD31 was expressed at high levels in other cell types, including HPCs, it cannot
be considered as a selective marker for CECs. Since CD133 was found to be expressed by few
CECs it cannot be regarded as a negative marker for these cells (Panel E in Fig 4). Further sub-
division of CECs was obtained by the analysis of c-kit. Around 15% of CECs appeared to be c-
kit positive and c-kit expression was associated with higher CD34 and KDR levels. RT-PCR
confirmed c-kit expression in CECs. Notably, c-kit mRNA levels were high and comparable to
those of HPCs, despite much lower surface protein expression (Panel F in Fig 4), indicative of
a discrepancy between mRNA and protein levels or surface expression of this marker.
In order to distinguish nucleated CECs from contaminating non-nucleated events, mainly
aggregates of endothelial micro-particles, representative samples were stained with the nuclear
dye Hoechst 33342 and all CECs appeared to be nucleated by FACS analysis (Panel A in Fig 5)
and post-sorting microscopic inspection. Since CECs are reported to be apoptotic, apoptosis
in these cells was assessed by Annexin-V staining. 78 (±4) % of CECs appeared to be apoptotic
vs. only 8% of HPCs (Panel B in Fig 5). The pan-caspase inhibitor Z-VAD-FMK, added imme-
diately after blood sampling, did not reduce the apoptotic fraction, which remained on average
80%, indicating that the cells were apoptotic from the time they entered the bloodstream. The
expression of c-kit in CECs was associated with lower apoptosis (Panel B in Fig 5).
Fig 3. HPCs: Analysis of c-kit and endothelial markers. A. FACS analysis for c-kit vs. CD133 confirms the PCR results and
refines HPC subdivision. In UCB, c-kit medium-high levels were observed in all the CD133-based subpopulations (with the exception
of sporadic events). In AB, an additional c-kitneg-low cluster was observed within the CD133high subpopulation, while the highest c-kit
levels were observed on the CD133neg cells (see also S3 Fig). B. Left: distribution of c-kitneg-low cells between the CD133-based
subpopulations in AB. Right: quantification of c c-kitneg-low cells in AB vs UCB. Right:. C. KDR, CD144, CD146 are sporadically
expressed by HPCs. CD105 is dimly expressed but only a fraction of cells crosses the negative gate (8%). The percentages of
positive cells are indicated in the plots. D. Analysis of KDR vs. CD146 expression in HPCs (UCB): the markers do not match but
identify independent subpopulations. For better visualization, we used a UCB sample with high frequency of HPCs and relatively high
KDR expression on HPCS (see also Panels D and E in S3 Fig). E. Analysis of CD144 vs. CD146 expression in HPCs: the two
markers mostly identify independent subpopulations (see also Panel F in S3 Fig).
https://doi.org/10.1371/journal.pone.0184895.g003
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Generation and characterization of OECs
Following 2–10 days after seeding unsorted PBMCs, adherent spindle-shaped cells matching
the morphologic characteristics of “early EPCs” (eEPCs) [1, 35–37] appeared in both AB and
UCB at a similar frequency (Panels A and B in S5 Fig). Following 1–3 weeks of culturing,
OECs or “late EPCs” appeared in 5 out of 6 UCB samples and 2 out of 10 AB samples (Panel C
in S5 Fig). From UCB also more colonies were generated (20 to 30) than from AB (1 and 10)
per PBMC sample corresponding to 10 ml of original blood. The OECs displayed the charac-
teristic cobblestone morphology, expressed von Willebrand factor (S5 Fig) and formed tube-
Fig 4. Identification, characterization, and quantification of CECs. A. Initial selection of CECs (UCB) on a CD34 vs. KDR plot
(1x106 events) by gating KDR+ cells at different CD34 levels. Lower panel: the acquisition of large sized samples was reached by
discarding triple CD34/CD133/KDR negative events resulting in better visualization of CECs. B. Subsequently, true KDR+CD45neg
CECs are selected in a CD45 vs. KDR plot. Most CECs belong to the CD34 high region (left plot), since KDR+ CD34low events are
almost entirely CD45+ (middle plot). Right plot: the CD45 gate applied efficiently discriminates CECs from sporadic KDR+ HPCs
(selected by CD34 and FSC-SSC). C. Comparison of UCB-CECs (left plot) and AB-CECs (right plot). For reference: HPCs are shown
in gray. In UCB, most CECs cluster at CD34 levels above HPCs and are KDRmed-hi, while in AB CECs have significantly lower CD34
and KDR levels. D. Frequency of CECs in UCB (14/106 CD45+ PBMCs) vs. AB (1,9/106CD45+ PBMCs). In AB the levels are
significantly lower (Z = -3,6; p = 3,00E-04). E. Marker expression by CECs. Upper left: 90% of KDR-selected CECs express CD146.
Lower left: 90% of CECs express CD144 but only after signal amplification. Upper right: CD31 is highly positive in CECs, but does
not discriminate CECs from HPCs. Lower right: CD133 is expressed by a minority of CECs. F. Upper left: Around 15% of the CECs
appear positive for c-kit and c-kit positivity correlates with higher KDR and CD34 levels (lower left). Right panel: RT-PCR confirms
the expression of c-kit by CECs at levels comparable with HPCs (n = 3) despite significantly lower surface expression.
https://doi.org/10.1371/journal.pone.0184895.g004
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like structures after several days. The OECs were harvested and FACS analyzed. HUVECs
were used as reference endothelial cells. Both OECs and HUVECs expressed high and stable
levels of CD31, CD144, CD146 and CD105 while CD14 and CD45 were not expressed (Panel
A in Fig 6 and Panel A in S6 Fig). With the exception of a single outlier, CD133 expression was
restricted to5% of the OECs (Panel B in Fig 6), matching the CD133 expression in CECs
(Panel E in Fig 4). The levels of c-kit, KDR and CD34 were heterogeneous and correlated posi-
tively with each other (Panels B and C in Fig 6 and Panels B and C in S6 Fig). Early passage
OECs and HUVECs contained a larger fraction of cells expressing high levels of CD34, KDR
and c-kit in comparison to the late passage ones (Panel B in Fig 6 and Panels B and D in
S6 Fig).
To investigate whether CECs are the source of OECs, we cultured sorted CECs in parallel
with sorted and unsorted total PBMCs, using a larger nozzle (100μm) and lower pressure (20
psi) to reduce cell damage. The sorted cells (both CECs and total PBMCs) did not generate
OECs, while unsorted PBMCs did. However, spindle-shaped early EPCs were successfully
obtained from sorted CD14+ cells (Panel B in S5 Fig), or total sorted PBMCs. This confirmed
the sound procedure of sample preparation and sorting, and suggested that FACS sorting is
too damaging for the vulnerable OEC precursors to generate OECs in culture. No correlation
between the yield of OECs and that of eEPCs was noticed in individual samples or in UCB vs.
Fig 5. Definition of nucleated events and apoptosis in CECs and HPCs. A. FACS analysis of live nuclear
staining with Hoechst 33342. Upper plot: nucleated events are separated from non-nucleated ones using
erythrocytes and mononuclear cells as a reference. Medium plot: lymphocytes and monocytes are 100%
nucleated. Lower plot: both CECs (red) and HPCs (green) appear as nucleated cells. CECs show a bimodal
distribution with a sub-G1 fraction (probably apoptotic, DNA-fragmented cells). B. Upper plot: representative
Annexin V staining of CECs (selected using CD34-FITC, CD146-PE, CD45-VioGreen) and HPCs (selected
using CD34-FITC and CD45-VioGreen) from UCB. Bottom left: percentages of apoptotic CECs and HPCs in
AB and UCB. Bottom right: apoptosis in c-kit+ vs c-kitneg CECs.
https://doi.org/10.1371/journal.pone.0184895.g005
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AB (S5 Fig), confirming that these two cell types have different circulating precursors [7, 22,
25, 36, 37].
Functional analysis
We analyzed a total of 10 angiogenic factors and receptors (apelin, PDGFβ, PDGFR, SCF,
FGF, EGF, EGFR, VEGFA, Tie-1 and Tie-2) by RT-PCR to all distinct EPC subsets and
HUVECs. Angiogenic factors appeared to be expressed in all EPC subsets. However, there was
variation in the levels of expression of these factors between the various EPC subsets (S7 Fig).
The levels of all angiogenic factors and receptors were lowest in HPCs with the exception of
EGF. Notably, CECs showed the highest expression of Apelin, PDGFβ, SCF, EGFR, and high
expression of Tie-2 as compared to the other cell types. The expressional pattern of OECs and
HUVECs almost completely overlapped. Overall, the pattern of OECs was much closer to
CECs than to HPCs.
In addition, we added immunohistochemistry for endothelial markers to OECs (vWF,
CD31, CD105) (S8 Fig). OECs were positive for all these markers, indicative of their endothe-
lial lineage.
Fig 6. FACS analysis of OECs. FACS analysis of markers with homogeneous/stable (A) and heterogeneous/unstable (B-C)
expression in early (passage 2–3) and late (passage >6) OEC cultures. A. No signals for CD45 and CD14. Staining for CD105,
CD31, CD144, CD146 was homogeneously high and stable. B. CD34, KDR, and c-kit expression was heterogeneous and decreased
with ageing of the cultures. The expression of CD133 was sporadic, with the exception of a single outlier, and slightly decreased with
time in culture. For each marker, three examples of early and late cultures, and the outlier, are shown. C. Example of positive
correlation (early passage OECs) between CD34, KDR, and c-kit. The markers define a triple high cluster, which is lost with ageing of
the culture.
https://doi.org/10.1371/journal.pone.0184895.g006
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Discussion
In this study we describe a procedure that allows for efficient identification, quantification,
and sorting of HPCs and CECs from peripheral blood samples, and culture-generated OECs.
Moreover, we improve the characterization of these populations resulting in, for instance, bet-
ter definition of subpopulations, and identification of a candidate circulating OEC precursor.
By using a Ficoll-based density gradient instead of a standard RBC lysis, significant enrichment
for PBMCs was achieved with preservation of the relative frequencies of HPCs and CECs over
total PBMCs [38, 39]. Ficoll-enrichment, combined with stringent gating out of residual non-
mononuclear cells, dead cells and debris, and accurate selection of markers, yielded clean and
pure populations meeting the current standards of state-of-the art FACS procedures [40]. The
procedure significantly reduced the sample size with preservation of the relative frequencies of
HPCs and CECs over total PBMCs, allowing for significantly faster analysis and sorting of the
target cells. The visualization and quantification of small populations was improved by select-
ing the events that were positive for the markers of interest to reduce data overload. This
allowed recording the equivalent of ~50106 CD45+ PBMCs within 1106 events (about 10–25
ml of whole blood). Moreover, by avoiding the use of toxic nuclear dyes the cells remain fully
viable for subsequent culture experiments and RNA extraction. By using the outlined protocol
we were able to identify HPCs and CECs more accurately, and isolate 200 to30.000 cells for
RT-PCR analysis from rare populations with frequencies as low as 1/1106 CD45+ PBMCs.
Improved characterization of HPCs
The current definition of HPCs is mainly based on a CD34+/highCD45low signature with
CD133 expression as an additional marker [5, 17, 34]. In the present analysis HPCs were iden-
tified as a CD34+/high CD45low cluster and further cleaned by gating a specific region in FSC/
SSC (Panels B and C in Fig 2). Moreover, extending the definition of CD133+ and CD133neg
HPCs [17, 34], we propose a subdivision of HPCs in CD133high, CD133low, and CD133neg sub-
populations. The HPC-identity of these subpopulations was confirmed by RT-PCR for CD133
and c-kit. By means of additional c-kit staining, HPCs were further subdivided by the demon-
stration of a c-kitneg/low subpopulation within the CD133high HPCs that was found only in AB,
not UCB. So far, c-kitneg/low HPCs have not been identified in human blood samples and were
only described as a quiescent population in mice [41]. CD133 or c-kit alone are no markers for
the identification of HPCs [42, 43], since they range from negative to high. However, our data
show that HPCs cannot be negative for CD133 and c-kit at the same time. Simultaneous stain-
ing of CD34+ cells (common denominator) for CD133 and c-kit leads to very accurate identi-
fication of HPCs as CD133+ and/or c-kit+ (Panels A and B in Fig 3). Following CD34, CD133,
and-c-kit-based identification, FSC/SSC and CD45 gating can be applied to further purify the
HPCs, in particular to exclude residual doublets with other cell types, and other false positives,
mainly contaminating CECs.
In line with previous data [1, 27, 44], the frequency of HPCs was significantly higher in
UCB than in AB. We observed a prevalence of CD133bright HPCs in UCB vs. AB. This finding
fits with the notion that CD133high HPCs are more primitive stem cells serving functions in
fetal and post-natal development [43, 45, 46]. We also found positive correlation of CD45 and
CD34 expression with CD133 levels, and a negative correlation between c-kit and CD133 lev-
els (S3 Fig). Analysis of the endothelial markers KDR, CD146, CD144, CD105 and CD31 lead
to an estimation of the risk of HPC contamination of the CEC population using each single
marker. In addition, the endothelial markers highlighted the presence of potentially interesting
and rare subpopulations of HPCs like the KDR+HPCs subpopulation that was described by
Case et al. [5], and considered as a distinct EPC population by other authors [1, 8, 27–30]. We
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show that the percentage of HPCs expressing endothelial markers (KDR, CD146, CD144,
CD105) varies significantly and depends on the marker used. We also show that, with the
exception of a few sporadic events, the markers are not concurrently expressed (Panels D and
E in Fig 3 and Panels D-F in S3 Fig). Therefore, these HPCs expressing endothelial markers
represent heterogeneous subpopulations requiring further exploration. Taken together, better
identification of HPCs over the previous CD34+/highCD45dim based protocol was reached and
better subdivision was achieved by means of a combined CD34, CD133, and c-kit staining.
Identification and characterization of CECs
In addition to the current criteria used for CEC-identification, we aimed at a more precise
characterization of these cells, delineation of sub-populations, and sorting for RT-PCR and
culture. Since CECs are generally identified as nucleated CD45negCD34+ events that addition-
ally express an endothelial marker, i.e., CD146 or KDR [18, 20, 21, 23], we used the CD34+/high
KDR+CD45- profile as a common denominator (Panels A and B in Fig 4). KDR-based CEC
identification was confirmed by CD146, CD105 and CD144 staining and by RT-PCR for these
markers (Panel E in Fig 4 and Panel C in S4 Fig). Since a single coherent population of CECs
was defined by using the endothelial markers, they may substitute KDR in the identification
CECs. However, staining for KDR yields the lowest background on HPCs and the best cross-
matching score and therefore, is regarded as a marker of first choice, followed by CD146 and
CD144 (Panel E in Fig 4 and Panels A and B in S4 Fig). The quality of CD45 staining/gating
was crucial for discriminating CECs from contaminating cells, mainly CD45lowHPCs sporadi-
cally expressing KDR, CD146, CD144, and potentially crossing the CD45neg gate (Panel B in
Fig 4 and Panel A in S4 Fig). Notably, all the CECs identified by the current procedure were
nucleated (Panel A in Fig 5), i.e. not contaminated by (endothelial) micro-particle aggregates
and therefore, the use of cell-permeant nuclear dyes like Hoechst or DRAQ5 was not necessary
[20, 47, 48]. By avoiding the use of bright and toxic nuclear dyes a fluorescent channel is saved
and spillover to other channels minimized, thereby improving the capacity of the detection
channels and the sensitivity of the analysis. Moreover, the viability of the cells is well preserved
for subsequent culture and RNA extraction.
Besides confirming higher frequency of CECs in UCB vs. AB [1, 7, 21, 22, 32, 44], we found
a major difference between CECs in AB as compared to UCB. The CECs in UCB express sig-
nificantly higher levels of CD34 and KDR (Panel C in Fig 4). Moreover, by means of Annexin-
V staining we identified two main subsets of CECs: a viable fraction of ~20%, and an apoptotic
fraction of ~80%, equally present in AB and UCB (Panel B in Fig 5). In addition, a c-kit+ sub-
set, expressing higher levels of KDR and CD34, was identified and found to be mainly present
in the viable fraction of CECs (Panel F in Fig 4 and Panel B in Fig 5) This subset may well con-
tain OEC-precursor cells. The angiogenic capacities of the CECs were further strengthened by
the expression of angiogenic factors (S7 Fig).
Characterization of OECs and prediction of their circulating precursor
The characterization of OECs was improved by various combinations of markers. In addition,
comparing early vs. late cultures evidenced the alterations occurring with aging of the cultures
and led to the definition of homogeneously high and stable markers (CD146, CD144, CD105,
CD31) on the one hand, and heterogeneous and unstable ones on the other (KDR, CD34, c-
kit, CD133). The comparisons also enabled us to trace back the OEC precursors to c-kit+
CECs. By combining FACS populations and RT-PCR data we found overlap in the expression
of KDR, CD146, CD105, CD144, and CD31 by OECs/HUVECs and CECs. Surface expression
of the markers was generally lower in CECs than in OECs/HUVECs. This may be explained by
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the fact that OECs/HUVECs are derived from in vitro cultures, while CECs are in vivo single
circulating cells, exposed to different environmental stimuli (lacking, for instance, the adhe-
sion to other endothelial cells, and exposed to the blood microenvironment) and subjected to a
potentially stressful purification procedure. Interestingly, the stem cell-marker c-kit was
expressed by a significant fraction of early passage OECs and HUVECs and positively associ-
ated with KDR and CD34 levels. CD34highKDRhighc-kithigh cells decreased with passaging in
culture (Panels B and C in Fig 5 and Panels B-D in S6 Fig). This finding points to a triple
+/high phenotype (CD34+/highKDR+/highc-kit+/high), which is lost with aging in culture, as the
progenitor/founder of both cell types [24, 49]. This view is supported by the recently described
c-kit+KDR+CD105+CD45- ’vascular endothelial stem cells’ (VESCs) in the blood vessels of
adult mice, which are capable of many cycles of replication and to generate functional blood
vessels in vitro [50]. Notably, the CD34+/highKDR+/highc-kit+/high phenotype that we trace back
as potential OEC precursor well matches the viable fraction of CECs expressing c-kit and
higher levels of KDR and CD34 (Panel F in Fig 4 and Panel B in Fig 5).
The current opinion on the origin of CECs is that these cells are mostly apoptotic, mature
endothelial cells without progenitor potential, shed from damaged blood vessels [14, 30, 51].
The present data, however, show that about 20% of circulating CECs are viable and express c-
kit (Panel F in Fig 4 and Panel B in Fig 5). The high expression of angiogenic factors by CECs
confirmed that these cells contain a fraction potentially contributing to neovascularization and
in vitro generation of OECs. Unfortunately, we were unable to directly derive OECs from
FACS-sorted CECs. These results are in line with results explicitly published by others [23]
and with the (implicit) evidence that OECs are reported to be generated from unsorted or
immuno-magnetic-bead-sorted PBMC fractions, not FACS-sorted ones [1, 7, 22–26]. The
present data, pointing to viable CECs expressing c-kit as OEC precursors, are in line with data
obtained from cells purified by antibody-coated beads suggesting that the OEC-founder cells
do not originate from bone marrow and express CD34 and CD146, but not CD45 or CD133, a
pattern compatible with CECs [7, 22, 23]. The significant higher yield of OECs from UCB
(containing more CECs than AB) than from AB further corroborates the view that OECs stem
from CECs.
Conclusions
In conclusion, the present FACS-based analysis yields optimal identification, characterization
and sub-division of cell populations meeting the current criteria for HPCs, CECs and OECs,
and enabled us to propose that the circulating OEC precursors may consist of viable c-kit+
CECs.
Supporting information
S1 Fig. Comparison of the isolated cell fractions between Ficoll vs. RBC treatment.
A. Overview of the distribution of FACS events in the main regions/populations of interest in
Ficoll vs. RBC lysis preparations. Besides differences in the mononuclear vs. non-mononuclear
regions, a lower amount of small particles and dead cells was observed in the Ficoll samples.
B. Percentages of white blood cells in the samples treated with RBC lysis buffer. The distribu-
tion matches the expected frequencies. C. The standard mononuclear gate used encompasses
endothelial cells of all sizes including large OECs and BFA (Bovine Foetal Aortic, from CLS).
(TIF)
S2 Fig. Fluorescence minus one (FMO) and isotype controls.
(TIF)
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S3 Fig. Characterization of HPCs. Histograms representative of CD34 (A) CD45 (B), and c-
kit (C) levels (measured as median fluorescence intensity, MFI) in different HPC subpopula-
tions from UCB and AB. CD34 levels are higher in CD133high HPCs, independently of c-kit
levels. CD45 levels are also positively correlated with CD133 expression, and independent of
c-kit levels. The highest c-kit levels are in the CD133neg HPCs. D-E. Additional details relative
to KDR vs. CD146 expression in HPCs (see also Panel D in Fig 3). In (E) for each KDR/
CD146-based HPC-subpopulation, the frequency vs. total HPCs and total PBMCs (upper pan-
els) is reported. FSC/SSC (medium panels) and CD45 (lower panels) based identification is
also shown to confirm HPC identity. FSC/SSC analysis is from CD34+CD45dim selected
HPCs, CD45 analysis is from CD34+ FSC/SSC selected HPCs. (F) Additional details relative to
CD144 vs. CD146 expression in HPCs, (see also Panel E in Fig 3). The frequency of each sub-
population vs. HPCs and total PBMCs is indicated.
(TIF)
S4 Fig. Identification and characterization of CECs. A. Identification of CECs using a CD34
vs. CD146 plot, and subsequent CD45 discrimination. The resulting population is pure and
not contaminated by HPCs (red, right plot). B. Left: KDR expression in CD34/CD146 selected
CECs indicated >98% matching. Right: CD105 expression in CD34/CD146 selected CECs
shows significant positivity (>50%). C. KDR expression is confirmed at mRNA level by
RT-PCR in CECs. HPCs are negative.
(TIF)
S5 Fig. Images of eEPCs and OECs. A. Upper: AB derived eEPCs (total PBMCs, unsorted);
lower: UCB derived eEPCs (total PBMCs, unsorted). B. eEPCs enriched by sorting out the
CD14+ fraction from AB-PBMCs (0.5x106 CD14+ events/cm2, 1 week culture). C. UCB
derived OECs with their typical cobblestone morphology (upper panel: early OEC colony;
middle panel: confluent OECs).
(TIF)
S6 Fig. FACS analysis of HUVECs and OECs. A. CD45 and CD14 were invariably 100% neg-
ative in HUVECs. CD146, CD144, CD105 were 100% highly expressed and stable. CD133+
cells were sporadic (0.8±0.7%). B. CD34, c-kit, and KDR were heterogeneously expressed, with
higher levels in early (passage 2–4) compared with late cultures (passage10). C. Positive cor-
relation between CD34, KDR and c-kit in early HUVEC. D. Quantification of CD34, KDR,
and c-kit high cells in early vs. late cultures of OECs and HUVECs.
(TIF)
S7 Fig. RT-PCR results to angiogenic factors and receptors in the EPC subsets. A. Bar dia-
grams of expressional levels of the genes measured. (mean values and standard deviations). B.
Differential expressed genes between HPCs and CECs calculated based on two-tailed T-test
(Z = standard deviation). C. Differential expressed genes between HPCs and OECs calculated
based on two-tailed T-test (Z = standard deviation).
(TIF)
S8 Fig. Immunohistochemistry of endothelial markers in OECs. vWF = von Willebrand
Factor.
(TIF)
S1 Table. Upper Left panel: FACS settings used. Upper Right panel: list of the antibodies
used for co-expression analysis in HPCs, CECs and OECs. Details on the staining procedure
are reported in Methods. Lower panel: primers used for RT-PCR and relative product size.
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HPRT1 was used low expressed housekeeping gene, B2M as highly expressed housekeeping
gene. Additional details are in Methods.
(DOCX)
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